Christopher J Sweeney Mbbs

List of Publications by Year
in descending order

244 papers	14,065 citations	31976 53 h-index	22832 112 g-index
246 all docs	246 docs citations	246 times ranked	14283 citing authors

#	Article	IF	Citations
1	Prevalence and clinical impact of tumor BRCA1 and BRCA2 mutations in patients presenting with localized or metastatic hormone-sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 2022, 25, 199-207.	3.9	3
2	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. European Journal of Cancer, 2022, 160, 24-60.	2.8	12
3	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 2022, 28, 144-153.	30.7	102
4	Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: experience at Dana Farber and in the PROCEED Registry. Prostate Cancer and Prostatic Diseases, 2022, 25, 314-319.	3.9	6
5	Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP) Tj ETQq1 1 0.784314 rgBT /Over 837-846.	1.6	29
6	CYCLONE 2: A phase 2/3, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS198-TPS198.	1.6	4
7	What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 6-11.	1.9	4
8	Changes in bone turnover markers (BTM) and association with outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) +/- docetaxel (D) in CHAARTED (ECOG-ACRIN E3805).. Journal of Clinical Oncology, 2022, 40, 145-145.	1.6	0
9	Association of serum steroid levels with survival in men with metastatic hormone-sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel on ECOG-ACRIN E3805.. Journal of Clinical Oncology, 2022, 40, 146-146.	1.6	0
10	Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study. Cancer Discovery, 2022, 12, 654-669.	9.4	34
11	Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2022, 28, 2237-2247.	7.0	16
12	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. Journal of Clinical Oncology, 2022, 40, 3011-3014.	1.6	12
13	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51
14	Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2022, 113, 825-832.	0.8	2
15	Reply to L. Marandino et al. Journal of Clinical Oncology, 2022, , JCO2200497.	1.6	0
16	Association between baseline body mass index and survival in men with metastatic hormoneâ€sensitive prostate cancer: ECOGâ€ACRIN CHAARTED E3805. Prostate, 2022, 82, 1176-1185.	2.3	2
17	The role of chemotherapy in metastatic prostate cancer. Current Opinion in Urology, 2022, 32, 292-301.	1.8	4
18	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. European Urology Oncology, 2022, 5, 377-387.	5.4	4

#	Article	IF	Citations
19	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€"A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2022, 40, TPS5103-TPS5103.	1.6	1
20	Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): An analysis from the ECOG-ACRIN 3805 (CHAARTED) trial.. Journal of Clinical Oncology, 2022, 40, 5081-5081.	1.6	6
21	Abstract CT032: Activity and safety of alectinib for ALK-altered solid tumors from MyPathway. Cancer Research, 2022, 82, CT032-CT032.	0.9	1
22	Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, LBA5004-LBA5004.	1.6	29
23	Assessing intermediate clinical endpoints (ICE) as potential surrogates for overall survival (OS) in men with metastatic hormone-sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2022, 40, 5006-5006.	1.6	2
24	Defining more precisely the effects of docetaxel plus ADT for men with mHSPC: Meta-analysis of individual participant data from randomized trials.. Journal of Clinical Oncology, 2022, 40, 5070-5070.	1.6	12
25	A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy. European Urology Focus, 2021, 7, 1130-1136.	3.1	13
26	Association between CD8 and PDâ€Ł1 expression and outcomes after radical prostatectomy for localized prostate cancer. Prostate, 2021, 81, 50-57.	2.3	22
27	When What You See Is Not Always What You Get: Raising the Bar of Evidence for New Diagnostic Imaging Modalities. European Urology, 2021, 79, 565-567.	1.9	25
28	Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases. Prostate Cancer and Prostatic Diseases, 2021, 24, 341-348.	3.9	8
29	Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2021, 39, 82-82.	1.6	0
30	Evaluating the role of stereotactic body radiation therapy with respect to androgen receptor signaling inhibitors for metastatic prostate cancer.. Journal of Clinical Oncology, 2021, 39, 121-121.	1.6	0
31	DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)â€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.. Journal of Clinical Oncology, 2021, 39, TPS266-TPS266.	1.6	0
32	Randomized phase II study evaluating the addition of pembrolizumab to radium-223 in metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 98-98.	1.6	4
33	EZH2 inhibition activates a dsRNAâ€"STINGâ€"interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nature Cancer, 2021, 2, 444-456.	13.2	118
34	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. JAMA Oncology, 2021, 7, 544.	7.1	82
35	NF-ÎºB Blockade with Oral Administration of Dimethylaminoparthenolide (DMAPT), Delays Prostate Cancer Resistance to Androgen Receptor (AR) Inhibition and Inhibits AR Variants. Molecular Cancer Research, 2021, 19, 1137-1145.	3.4	9
36	Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.. Journal of Clinical Oncology, 2021, 39, 5057-5057.	1.6	4

#	Article	IF	Citations
37	MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3004-3004.	1.6	27
38	Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.. Journal of Clinical Oncology, 2021, 39, 5076-5076.	1.6	0
39	A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer. Prostate, 2021, 81, 683-693.	2.3	5
40	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	1.6	83
41	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	1.6	108
42	Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet, The, 2021, 398, 131-142.	13.7	167
43	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Network Open, 2021, 4, e2116536.	5.9	11
44	Abstract LB012: Efficacy of atezolizumab in the treatment of solid tumors with high tumor mutational burden (TMB): A MyPathway study cohort. , 2021, , .		1
45	Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2021, 13, 4055.	3.7	1
46	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	1.6	26
47	Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2021, 22, 1290-1300.	10.7	178
48	Metastatic Prostate Cancer: In Search of More Granularity. Journal of Clinical Oncology, 2021, 39, 2968-2969.	1.6	4
49	Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy. European Urology, 2021, 80, 275-279.	1.9	28
50	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. Urology, 2021, 155, 165-171.	1.0	11
51	Re: Rivaroxaban for Thromboprophylaxis in High-risk Ambulatory Patients with Cancer. European Urology, 2020, 77, 388-390.	1.9	3
52	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiotherapy and Oncology, 2020, 152, 80-88.	0.6	9
53	Phase I, Pharmacogenomic, Drug Interaction Study of Sorafenib and Bevacizumab in Combination with Paclitaxel in Patients with Advanced Refractory Solid Tumors. Molecular Cancer Therapeutics, 2020, 19, 2155-2162.	4.1	4
54	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib. Clinical Cancer Research, 2020, 26, 6122-6131.	7.0	9

#	Article	IF	Citations
55	Impact of baseline serum ILâ€8 on metastatic hormoneâ€sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805). Prostate, 2020, 80, 1429-1437.	2.3	11
56	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. JAMA Network Open, 2020, 3, e2021692.	5.9	70
57	Event-Free Survival, a Prostate-Specific Antigenâ€“Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. Journal of Clinical Oncology, 2020, 38, 3032-3041.	1.6	37
58	A Call for Standardized Reporting of Adverse Events. European Urology, 2020, 78, 481-482.	1.9	3
59	HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncology, 2020, 6, e196496.	7.1	50
60	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology, 2020, 77, 508-547.	1.9	278
61	Luminal B subtype as a predictive biomarker of docetaxel benefit for newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC): A correlative study of E3805 CHAARTED.. Journal of Clinical Oncology, 2020, 38, 162-162.	1.6	16
62	Impact of baseline serum IL-8 on metastatic hormone-sensitive (mHSPC) prostate cancer outcomes in the phase III CHAARTED trial (E3805).. Journal of Clinical Oncology, 2020, 38, 171-171.	1.6	1
63	Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 182-182.	1.6	13
64	Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium.. Journal of Clinical Oncology, 2020, 38, 386-386.	1.6	14
65	Response to olaparib or carboplatin in a real-world cohort of men with DNA damage repair (DDR) deficient metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 43-43.	1.6	3
66	DASL-HiCAP (ANZUP1801): The impact of darolutamide on standard therapy for localized very high-risk cancer of the prostateâ€"A randomized phase III double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high-risk, clinically localized prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS385-TPS385.	1.6	2
67	The impact of the expression of the transcription factor MYBL2 on outcomes of patients with localized and advanced prostate cancer.. Journal of Clinical Oncology, 2020, 38, 149-149.	1.6	1
68	CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS5591-TPS5591.	1.6	0
69	Multiregion expression profiling of prostate cancer from men randomized in the STAMPEDE trial: Stage I results of a multistage biomarker analysis.. Journal of Clinical Oncology, 2020, 38, 153-153.	1.6	0
70	Circulating tumor (ct)-DNA alterations in patients with testicular germ cell tumors.. Journal of Clinical Oncology, 2020, 38, 415-415.	1.6	0
71	Causes and patterns of mortality in patients with lethal germ cell tumor (GCT).. Journal of Clinical Oncology, 2020, 38, 421-421.	1.6	0
72	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. Journal of Clinical Oncology, 2020, 38, 280-280.	1.6	0

#	Article	IF	Citations
73	Clinical outcomes of abiraterone acetate + prednisone (AA) + bone resorption inhibitors (BRI) versus AA alone as first-line therapy for castration-resistant prostate cancer (CRPC) with bone metastases (BM) in an international multicenter database.. Journal of Clinical Oncology, 2020, 38, 30-30.	1.6	0
74	Improving quality of health-related quality of life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate cancer (mPC).. Journal of Clinical Oncology, 2020, 38, 58-58.	1.6	0
75	Circulating-free DNA (cfDNA) as biomarker of taxane resistance in metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 174-174.	1.6	0
76	Benefit of prophylactic anticoagulation before and during first-line chemotherapy on patients with metastatic germ cell tumors.. Journal of Clinical Oncology, 2020, 38, 402-402.	1.6	0
77	DMAPT is an Effective Radioprotector from Long-Term Radiation-Induced Damage to Normal Mouse Tissues In Vivo. Radiation Research, 2019, 192, 231.	1.5	5
78	Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16â€transgenic mice. Drug Development Research, 2019, 80, 824-830.	2.9	12
79	Time for an Integrated Global Strategy to Decrease Deaths from Prostate Cancer. European Urology Focus, 2019, 5, 111-113.	3.1	3
80	The Balancing Act: Assessing Treatment Burden Versus Treatment Benefit with Evolving Metastatic Hormone-sensitive Prostate Cancer Data. European Urology, 2019, 76, 729-731.	1.9	0
81	Metastatic Hormone-Sensitive Prostate Cancer: Clinical Decision Making in a Rapidly Evolving Landscape of Life-Prolonging Therapy. Journal of Clinical Oncology, 2019, 37, 2961-2967.	1.6	13
82	Loss of PTEN Expression Detected by Fluorescence Immunohistochemistry Predicts Lethal Prostate Cancer in Men Treated with Prostatectomy. European Urology Oncology, 2019, 2, 475-482.	5.4	17
83	Association of Inherited Pathogenic Variants in Checkpoint Kinase 2 (CHEK2) With Susceptibility to Testicular Germ Cell Tumors. JAMA Oncology, 2019, 5, 514.	7.1	43
84	Body Mass Index and Outcomes in Germ-Cell Tumors. Clinical Genitourinary Cancer, 2019, 17, 283-290.	1.9	2
85	Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. New England Journal of Medicine, 2019, 381, 121-131.	27.0	982
86	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	2.8	8
87	Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial. European Journal of Cancer, 2019, 114, 107-116.	2.8	42
88	AYA testis cancer: The unmet challenge. Pediatric Blood and Cancer, 2019, 66, e27796.	1.5	6
89	Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncology, The, 2019, 20, 518-530.	10.7	362
90	Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the Cart. Journal of Clinical Oncology, 2019, 37, 765-769.	1.6	29

#	Article	IF	Citations
91	Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. European Urology, 2019, 76, 115-124.	1.9	203
92	Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. European Urology, 2019, 76, 89-97.	1.9	158
93	A phase 2 trial of abiraterone acetate without glucocorticoids for men with metastatic castrationâ€resistant prostate cancer. Cancer, 2019, 125, 524-532.	4.1	8
94	Low Tristetraprolin Expression Is Associated with Lethal Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 584-590.	2.5	8
95	Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry. Prostate Cancer and Prostatic Diseases, 2019, 22, 420-427.	3.9	49
96	Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 32-37.	1.9	4
97	Comparison of testis cancerâ€specific survival: an analysis of national cancer registry data from the USA, UK and Germany. BJU International, 2019, 123, 385-387.	2.5	6
98	Autologous Stem-Cell Transplantation Outcomes for Relapsed Metastatic Germ-Cell Tumors in the Modern Era. Clinical Genitourinary Cancer, 2019, 17, 58-64.e1.	1.9	7
99	CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, 4503-4503.	1.6	35
100	Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progression on abiraterone.. Journal of Clinical Oncology, 2019, 37, 5009-5009.	1.6	9
101	Genomic predictors of benefit of docetaxel (D) and next-generation hormonal therapy (NHT) in metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 5018-5018.	1.6	3
102	HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.. Journal of Clinical Oncology, 2019, 37, 5020-5020.	1.6	3
103	Circulating tumor (ct)-DNA alterations in patients with testicular germ tumors.. Journal of Clinical Oncology, 2019, 37, e16063-e16063.	1.6	2
104	Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP) Tj ETQq0 0 0 rgBT /Overlock 10 T LBA2-LBA2.	1.6	6
105	Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2019, 37, 244-244.	1.6	1
106	Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).. Journal of Clinical Oncology, 2019, 37, 86-86.	1.6	5
107	Genetic counseling processes and outcomes among prostate cancer patients (ProGen).. Journal of Clinical Oncology, 2019, 37, TPS343-TPS343.	1.6	1
108	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. Journal of Clinical Oncology, 2019, 37, 478-478.	1.6	2

#	Article	IF	Citations
109	Efficacy of bone resorption inhibitors (BRI) + abiraterone acetate + prednisone (AA) vs. AA alone as first-line therapy for men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) in an international multicenter hospital-based registry.. Journal of Clinical Oncology, 2019, 37, e16508-e16508.	1.6	0
110	Evaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized Trial. Journal of Medical Internet Research, 2019, 21, e12044.	4.3	2
111	Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).. Journal of Clinical Oncology, 2019, 37, e16601-e16601.	1.6	0
112	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies. European Urology, 2018, 73, 847-855.	1.9	174
113	NF-ÎºB inhibition by dimethylaminoparthenolide radiosensitizes non-small-cell lung carcinoma by blocking DNA double-strand break repair. Cell Death Discovery, 2018, 4, 10.	4.7	15
114	Current treatment strategies for advanced prostate cancer. International Journal of Urology, 2018, 25, 220-231.	1.0	164
115	The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation. Prostate Cancer and Prostatic Diseases, 2018, 21, 306-318.	3.9	21
116	Evaluation of diseaseâ€free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trialâ€level metaâ€analysis. Cancer, 2018, 124, 925-933.	4.1	38
117	Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation TherapyÂ+ Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer. Clinical Genitourinary Cancer, 2018, 16, 130-134.	1.9	15
118	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. American Journal of Medicine, 2018, 131, 517-523.	1.5	13
119	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
120	Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clinical Genitourinary Cancer, 2018, 16, e233-e242.	1.9	8
121	Smoking and Disease Outcomes in Patients With Malignant Germ Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, 78-84.	1.9	4
122	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. Oncologist, 2018, 23, 193-202.	3.7	60
123	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. Journal of Clinical Oncology, 2018, 36, 376-382.	1.6	75
124	Reply to J.J. Tao et al. Journal of Clinical Oncology, 2018, 36, 2451-2451.	1.6	1
125	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. Journal of Clinical Oncology, 2018, 36, 1088-1095.	1.6	72
126	Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. Journal of Clinical Oncology, 2018, 36, 536-542.	1.6	362

#	Article	IF	Citations
127	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. Journal of Clinical Oncology, 2018, 36, 1080-1087.	1.6	702
128	Chronic low dose ethanol induces an aggressive metastatic phenotype in TRAMP mice, which is counteracted by parthenolide. Clinical and Experimental Metastasis, 2018, 35, 649-661.	3.3	5
129	Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?. European Urology, 2018, 74, 420-421.	1.9	1
130	A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castrationâ€resistant prostate cancer. Prostate, 2018, 78, 1053-1062.	2.3	4
131	ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D. Journal of Clinical Investigation, 2018, 128, 2979-2995.	8.2	53
132	Impact of ethnicity on the outcome of men with metastatic, hormoneâ€sensitive prostate cancer. Cancer, 2017, 123, 1536-1544.	4.1	57
133	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	1.9	7
134	Age â‰¥40 Years Is Associated with Adverse Outcome in Metastatic Germ Cell Cancer Despite Appropriate Intended Chemotherapy. European Urology Focus, 2017, 3, 621-628.	3.1	10
135	Evolving Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer. Journal of Oncology Practice, 2017, 13, 9-18.	2.5	14
136	â€œGotta Catch 'em Allâ€, or Do We? Pokemet Approach to Metastatic Prostate Cancer. European Urology, 2017, 72, 1-3.	1.9	56
137	Parthenolide Selectively Sensitizes Prostate Tumor Tissue to Radiotherapy while Protecting Healthy Tissues In Vivo. Radiation Research, 2017, 187, 501-512.	1.5	32
138	TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. Clinical Cancer Research, 2017, 23, 7072-7083.	7.0	87
139	Chemotherapy for oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 553-558.	1.8	4
140	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: AÂsystematic review and meta-analysis. European Journal of Cancer, 2017, 84, 88-101.	2.8	128
141	A new standard-of-care for advanced-stage disease. Nature Reviews Clinical Oncology, 2017, 14, 592-593.	27.6	4
142	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncology, The, 2017, 18, 132-142.	10.7	124
143	Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3097-3104.	1.6	327
144	Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology, 2017, 35, 4585-4585.	1.6	1

#	Article	IF	Citations
145	Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: Preliminary data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 402-402.	1.6	49
146	Pertuzumab + trastuzumab for HER2-amplified/overexpressed metastatic colorectal cancer (mCRC): Interim data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 676-676.	1.6	30
147	Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): Preliminary data from MyPathway.. Journal of Clinical Oncology, 2017, 35, 348-348.	1.6	17
148	Identification of low prostate-specific antigen, high Gleason prostate cancer as a unique hormone-resistant entity with poor survival: A contemporary analysis of 640,000 patients.. Journal of Clinical Oncology, 2017, 35, 5080-5080.	1.6	1
149	Association of loss of tumor suppressor ZFP36 with lethal prostate cancer.. Journal of Clinical Oncology, 2017, 35, 5062-5062.	1.6	1
150	A phase III trial comparing atezolizumab with enzalutamide vs enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, TPS5090-TPS5090.	1.6	4
151	Outcomes of prechemotherapy (pCHT) abiraterone (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after androgen deprivation therapy (ADT) + docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a hospital-based registry.. Journal of Clinical Oncology, 2017, 35, e16515-e16515.	1.6	0
152	Approach to Oligometastatic Prostate Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 119-129.	3.8	17
153	Association between very small tumour size and increased cancerâ€specific mortality after radical prostatectomy in lymph nodeâ€positive prostate cancer. BJU International, 2016, 118, 279-285.	2.5	14
154	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factorâ€targeted therapies. Cancer, 2016, 122, 2389-2398.	4.1	16
155	Genomic evolution and chemoresistance in germ-cell tumours. Nature, 2016, 540, 114-118.	27.8	139
156	Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. European Urology Focus, 2016, 2, 463-464.	3.1	1
157	Optimal Treatment Sequence for Metastatic Castration-resistant Prostate Cancer. European Urology Focus, 2016, 2, 488-498.	3.1	38
158	Docetaxel Activity in the Era of Life-prolonging Hormonal Therapies for Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 410-412.	1.9	29
159	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	1.6	121
160	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. Cancer, 2016, 122, 3127-3135.	4.1	46
161	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. Brachytherapy, 2016, 15, 695-700.	0.5	13
162	National sociodemographic disparities in the treatment of highâ€risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. Cancer, 2016, 122, 3371-3377.	4.1	27

#	Article	IF	Citations
163	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 421-428.	4.9	10
164	Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 6259-6264.	7.1	127
165	CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases. European Journal of Radiology, 2016, 85, 1439-1444.	2.6	4
166	Risk of prostate cancerâ€specific death in men with baseline metabolic aberrations treated with androgen deprivation therapy for biochemical recurrence. BJU International, 2016, 118, 919-926.	2.5	10
167	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. Clinical Genitourinary Cancer, 2016, 14, e299-e305.	1.9	11
168	Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy. Journal of Clinical Oncology, 2016, 34, 714-720.	1.6	31
169	Genetic Effect of Chemotherapy Exposure in Children of Testicular Cancer Survivors. Clinical Cancer Research, 2016, 22, 2183-2189.	7.0	15
170	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 57.e15-57.e22.	1.6	17
171	It Is Time to Harmonize the Design and Conduct of Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer. European Urology, 2016, 70, 263-264.	1.9	4
172	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with â‰¥50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. Urology, 2016, 87, 125-132.	1.0	16
173	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. BJU International, 2016, 118, 95-101.	2.5	45
174	Stress-Related Signaling Pathways in Lethal and Nonlethal Prostate Cancer. Clinical Cancer Research, 2016, 22, 765-772.	7.0	25
175	Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Optionsâ€"An Analysis From the Global Germ Cell Cancer Group. Journal of Clinical Oncology, 2016, 34, 345-351.	1.6	69
176	Risk of prostate cancer mortality in men with a history of prior cancer. BJU International, 2016, 117, E20-8.	2.5	22
177	Computational Reconstruction of NFÎºB Pathway Interaction Mechanisms during Prostate Cancer. PLoS Computational Biology, 2016, 12, e1004820.	3.2	27
178	Who Bears the Greatest Burden of Aggressive Treatment of Indolent Prostate Cancer?. American Journal of Medicine, 2015, 128, 609-616.	1.5	21
179	[18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography of LAPC4-CR Castration-Resistant Prostate Cancer Xenograft Model in Soft Tissue Compartments. Translational Oncology, 2015, 8, 147-153.	3.7	6
180	The Juxtaposition of Population Science and Individual Treatment Recommendations for Intermittent Androgen Deprivation Therapy. JAMA Oncology, 2015, 1, 1270.	7.1	0

#	Article	IF	Citations
181	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). Journal of the National Cancer Institute, 2015, 107, djv261.	6.3	53
182	Sequencing current therapies in the treatment of metastatic prostate cancer. Cancer Treatment Reviews, 2015, 41, 332-340.	7.7	38
183	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 2015, 373, 737-746.	27.0	2,112
184	Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer. JAMA Oncology, 2015, 1, 495.	7.1	118
185	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	1.6	13
186	Association Between Older Age and Increasing Gleason Score. Clinical Genitourinary Cancer, 2015, 13, 525-530.e3.	1.9	23
187	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.4	109
188	Management of Metastatic Hormone-Sensitive Prostate Cancer. Current Urology Reports, 2015, 16, 14.	2.2	9
189	Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Antiâ€“Prostate Cancer Activity. Clinical Cancer Research, 2015, 21, 5578-5587.	7.0	15
190	Definition and Validation of â€œFavorable High-Risk Prostate Cancerâ€• Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.8	40
191	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. Journal of Clinical Oncology, 2015, 33, 3018-3028.	1.6	63
192	Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell Tumors. Journal of Ultrasound in Medicine, 2015, 34, 1977-1982.	1.7	10
193	Diagnosis and Treatment of Testicular Cancer. Surgical Pathology Clinics, 2015, 8, 717-723.	1.7	10
194	Association of androgenâ€deprivation therapy with excess cardiacâ€specific mortality in men with prostate cancer. BJU International, 2015, 116, 358-365.	2.5	66
195	Income inequality and treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 18.e7-18.e13.	1.6	53
196	Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. European Urology, 2015, 67, 310-318.	1.9	35
197	A reproducible approach to high-throughput biological data acquisition and integration. PeerJ, 2015, 3, e791.	2.0	12
198	(18)F-FDG-PET/CT and (18)F-NaF-PET/CT in men with castrate-resistant prostate cancer. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 72-82.	1.0	16

#	Article	IF	Citations
199	Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study. Journal of Clinical Oncology, 2014, 32, 3391-3399.	1.6	110
200	Elevated insulinâ€like growth factor binding proteinâ€1 (IGFBPâ€1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival. Prostate, 2014, 74, 225-234.	2.3	33
201	Elevated ILâ€8, TNFâ€Î±, and MCPâ€1 in men with metastatic prostate cancer starting androgenâ€deprivation therapy (ADT) are associated with shorter time to castrationâ€resistance and overall survival. Prostate, 2014, 74, 820-828.	2.3	66
202	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. European Journal of Cancer, 2014, 50, 3145-3152.	2.8	99
203	Trends in Disparate Treatment of African American Men With Localized Prostate Cancer Across National Comprehensive Cancer Network Risk Groups. Urology, 2014, 84, 386-392.	1.0	86
204	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	1.6	229
205	Racial Disparities in Prostate Cancerâ€"Specific Mortality in Men With Low-Risk Prostate Cancer. Clinical Genitourinary Cancer, 2014, 12, e189-e195.	1.9	46
206	Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?. Urology, 2014, 83, 1316-1321.	1.0	17
207	Racial disparities in an aging population: The relationship between age and race in the management of African American men with high-risk prostate cancer. Journal of Geriatric Oncology, 2014, 5, 352-358.	1.0	21
208	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1285-1291.	1.6	81
209	Failure to Suppress Markers of Bone Turnover on First-Line Hormone Therapy for Metastatic Prostate Cancer Is Associated With Shorter Time to Skeletal-Related Event. Clinical Genitourinary Cancer, 2014, 12, 33-40.e4.	1.9	7
210	Prostate cancer therapy: going forwards by going backwards. Lancet Oncology, The, 2013, 14, 104-105.	10.7	43
211	Preface. Hematology/Oncology Clinics of North America, 2013, 27, xi-xii.	2.2	0
212	Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. Journal of Clinical Oncology, 2013, 31, 412-419.	1.6	405
213	Association of metabolic syndrome with reduced survival among men receiving androgen deprivation therapy for nonmetastatic prostate cancer.. Journal of Clinical Oncology, 2012, 30, 56-56.	1.6	4
214	Use of elevated baseline IL-8, CCL-2, and TNFÎ± to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2012, 30, 13-13.	1.6	0
215	Use of elevated insulin-like growth factor binding protein-1 (IGFBP-1) to predict outcomes in men with metastatic prostate cancer treated with androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2012, 30, 191-191.	1.6	0
216	Evaluation of nuclear factor ÎºB and chemokine receptor CXCR4 coâ€expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. BJU International, 2011, 108, E51-8.	2.5	20

#	Article	IF	Citations
217	Inhibition of NF-ÎºB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-rays. Free Radical Biology and Medicine, 2011, 51, 2249-2258.	2.9	25
218	A water soluble parthenolide analog suppresses in vivo tumor growth of two tobaccoâ€associated cancers, lung and bladder cancer, by targeting NFâ€ÎºB and generating reactive oxygen species. International Journal of Cancer, 2011, 128, 2481-2494.	5.1	72
219	Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75. Journal of Clinical Oncology, 2011, 29, 1525-1530.	1.6	180
220	Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2011, 2011, 171-176.	3.8	0
221	A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment. Cancer Chemotherapy and Pharmacology, 2010, 66, 345-356.	2.3	32
222	A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2010, 66, 441-448.	2.3	9
223	A waterâ€soluble parthenolide analogue suppresses in vivo prostate cancer growth by targeting NFÎºB and generating reactive oxygen species. Prostate, 2010, 70, 1074-1086.	2.3	60
224	A Phase I Study of Sunitinib Plus Capecitabine in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2010, 28, 4513-4520.	1.6	44
225	Suppression of NF-ÎºB Activity by Parthenolide Induces X-Ray Sensitivity through Inhibition of Split-Dose Repair in TP53 Null Prostate Cancer Cells. Radiation Research, 2009, 171, 389-396.	1.5	24
226	Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer. Pancreas, 2008, 37, e45-e53.	1.1	26
227	Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibition in vivo. Molecular Cancer Therapeutics, 2007, 6, 1736-1744.	4.1	39
228	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood, 2007, 110, 4427-4435.	1.4	357
229	Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer. Journal of Surgical Research, 2007, 143, 169-176.	1.6	7
230	Parthenolide Sensitizes Cells to X-Ray-Induced Cell Killing through Inhibition of NF-ÎºB and Split-Dose Repair. Radiation Research, 2007, 168, 689-697.	1.5	32
231	The Case for Systemic Therapy Alone for Prostate Cancer. Journal of Urology, 2006, 176, S42-6.	0.4	1
232	Thymoma and Thymic Carcinoma. , 2006, , 237-256.		0
233	Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model. Prostate, 2006, 66, 1498-1511.	2.3	44
234	Phase II Study of Pemetrexed for Second-Line Treatment of Transitional Cell Cancer of the Urothelium. Journal of Clinical Oncology, 2006, 24, 3451-3457.	1.6	234

#	Article	IF	Citations
235	ECOG: CHAARTED–ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer. Clinical Advances in Hematology and Oncology, 2006, 4, 588-90.	0.3	14
236	A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2005, 11, 6625-6633.	7.0	158
237	Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-Î¹B pathway in pancreatic carcinoma cells. Molecular Cancer Therapeutics, 2005, 4, 587-594.	4.1	108
238	The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Molecular Cancer Therapeutics, 2005, 4, 1004-1012.	4.1	145
239	Nuclear Factor-Î¹B Is Constitutively Activated in Prostate Cancer In vitro and Is Overexpressed in Prostatic Intraepithelial Neoplasia and Adenocarcinoma of the Prostate. Clinical Cancer Research, 2004, 10, 5501-5507.	7.0	157
240	Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investigational New Drugs, 2004, 22, 299-305.	2.6	109
241	Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detection and Prevention, 2002, 26, 238-244.	2.1	16
242	Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer, 2002, 94, 104-110.	4.1	79
243	Evaluation of HER-2/neu expression in prostatic adenocarcinoma. Cancer, 2002, 95, 1650-1655.	4.1	49
244	Selenomethionine induction of DNA repair response in human fibroblasts. , 0, .		2